The Effects of Omega-3 Supplementation on the Expanded Disability Status Scale and Inflammatory Cytokines in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis Publisher Pubmed



Sedighiyan M¹ ; Djafarian K² ; Dabiri S³ ; Abdolahi M³ ; Shabbidar S⁴ Show Affiliations
Source: CNS and Neurological Disorders - Drug Targets Published:2019

Abstract

Recent trial studies have shown that omega-3 supplementation can beneficially improve scores on the Expanded Disability Status Scale (EDSS), which is considered a gold standard for measuring disability and disease severity in Multiple Sclerosis (MS) patients, as well as reducing neuroinflammation. The present systematic review and meta-analysis aimed to evaluate the effect of omega-3 supplementation on EDSS and cytokines in MS. A systematic search was performed on Pubmed, Sco-pus and Cochrane Library up to October 2018. Studies were reviewed based on the Cochrane handbook, and the preferred reporting items for systematic reviews and meta-analyses (PRISMA). Weighted Mean Difference (WMD) with 95% Confidence Intervals (CI) were pooled using a random effects model in order to compare the effects of omega-3 with placebos. Among 4 trials, omega-3 supplementation had no significant effect on EDSS scale (WMD:-0.07; 95% CI:-0.27 to 0.13; P=0.50), as well as serum levels of IL-1β (WMD:-7.67; 95% CI:-23.31 to 7.97; P=0.34) and IL-6 (WMD:-153.57; 95% CI:-455.36 to 148.23; P=0.32). However, omega-3 significantly reduced TNF-α concentration (WMD:-16.76; 95% CI:-18.63 to-14.88; P < 0.00001) compared to placebo. Overall, omega-3 supplementation may not have a clinically considerable impact on EDSS or proinflammatory markers. However, the existing trials are limited in this context, and further clinical trials are required to confirm the potential effects of the omega-3 supplement on MS disease management. © 2019 Bentham Science Publishers.